| SCHEDULE OF SIGNIFICANT EXPENSE CATEGORIES |
The table below summarizes the significant expense
categories regularly reviewed by the CODM:
SCHEDULE
OF SIGNIFICANT EXPENSE CATEGORIES
| |
|
|
|
|
|
|
| |
|
For the three months ended March 31, |
|
| |
|
2025 |
|
|
2024 |
|
| |
|
|
|
|
|
|
| License and other revenues |
|
$ |
— |
|
|
$ |
— |
|
| |
|
|
|
|
|
|
|
|
| Research and development costs |
|
|
|
|
|
|
|
|
| Salaries & related costs |
|
$ |
4,681 |
|
|
$ |
3,555 |
|
| Non-cash stock-based compensation |
|
|
670 |
|
|
|
346 |
|
| Other research and development costs (a)
|
|
|
4,590 |
|
|
|
3,306 |
|
| Total research and development costs |
|
$ |
9,941 |
|
|
$ |
7,207 |
|
| |
|
|
|
|
|
|
|
|
| General and administrative costs |
|
|
|
|
|
|
|
|
| Salaries & related costs |
|
$ |
3,653 |
|
|
$ |
2,262 |
|
| Non-cash stock-based compensation |
|
|
2,031 |
|
|
|
1,200 |
|
| Pre-commercial preparation costs |
|
|
1,207 |
|
|
|
1,351 |
|
| Other general and administrative costs (b)
|
|
|
2,895 |
|
|
|
2,310 |
|
| Total general and administrative costs |
|
$ |
9,786 |
|
|
$ |
7,123 |
|
| |
|
|
|
|
|
|
|
|
| Other segment items (c)
|
|
|
(7,698 |
) |
|
|
17,248 |
|
| Net loss |
|
$ |
(12,029 |
) |
|
$ |
(31,578 |
) |
| (a) |
Other
research and development expenses include, but are not limited to lab supplies, preclinical and development costs, clinical trial
costs, preclinical manufacturing and manufacturing facility costs, costs associated with regulatory approvals, depreciation on lab
supplies and manufacturing facilities, and consultant-related expenses. |
| (b) |
Other general and administrative expenses primarily consist of office facility costs, public reporting company related costs, professional fees (e.g., legal expenses) and other general operating expenses not otherwise included in research and development expenses. |
| (c) |
Other segment items includes royalties, interest income, interest expense, change in fair value of warrant and derivative liabilities and other income. |
|